14 maj: Resultat af auktion over skatkammerbeviser 14. maj 2019
14 maj: Danske Bank A/S, Insideres handler
14-05-2019 10:32:40

Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia

Company announcement – No. 15 / 2019

Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia            

  • Primary and all key secondary endpoints successfully achieved in the trial

  • Median time to recovery from low blood glucose was 10 minutes following dasiglucagon injection administered via the HypoPal® rescue pen

  • The dasiglucagon HypoPal® rescue pen is being developed as an easy-to-use, fast and effective rescue treatment for diabetes patients having a severe hypoglycemic event


Copenhagen, May 14, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces successful results in the confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes. Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand. It is in development in the ready-to-use HypoPal® rescue pen, an auto-injector for easy, fast and effective treatment of severe hypoglycemia in people with diabetes.

This Phase 3 trial confirms that a single dose of dasiglucagon administered via the HypoPal® rescue pen rapidly increases blood glucose levels in patients with type 1 diabetes following insulin-induced hypoglycemia. The trial compared the glycemic response observed after dosing of dasiglucagon with that of placebo. The primary endpoint was time to plasma glucose recovery, which was defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. 45 subjects were included in the trial. Additional details about the trial are found at clinicaltrials.gov.

The primary result demonstrates that the median time to blood glucose recovery was 10 minutes for dasiglucagon, which was superior to placebo (median: 35 min; p<0.001) and="" identical="" to="" a="" median="" time="" to="" rescue="" of="" 10="" minutes="" observed="" in="" the="" pivotal="" phase="" 3="" trial="" which="" used="" a="" pre-filled="" syringe="" for="" administration="" of="" dasiglucagon.="" likewise,="" the="" dasiglucagon="" pharmacokinetic="" profiles="" were="" consistent="" between="" the="" two="" trials.="" overall,="" no="" safety="" concerns="" were="" raised="" for="" dasiglucagon="" within="" the="" trial.="" nausea="" and="" vomiting="" were="" reported="" with="" dasiglucagon="" (nausea:="" 62%="" and="" vomiting:="" 29%)="" and="" were="" on="" par="" with="" the="" frequency="" observed="" in="" the="" pivotal="" phase="" 3="" trial="" (nausea:="" 55%="" and="" vomiting:="">

Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma, commented: “I am very encouraged by the outcome of this Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in diabetes. The study used the to-be-marketed HypoPal® rescue pen, and the results underscore the fast and effective profile of dasiglucagon also seen in the pivotal Phase 3 trial utilizing a pre-filled syringe.”

This is the third consecutive Phase 3 trial with positive results for dasiglucagon. The previous immunogenicity and pivotal Phase 3 trials established dasiglucagon’s safety profile and fast onset of action when administered via a pre-filled syringe in adult patients with type 1 diabetes. The final Phase 3 trial that will complete our NDA application is in pediatric diabetes patients and is still ongoing. Recruitment for this study involving children has proved challenging and results are now expected in September 2019. Accounting for this delay in pediatric patient recruitment, submission of the new drug application (NDA) to the U.S. FDA is now expected early 2020.

“I am very impressed with the dasiglucagon HypoPal® rescue pen data and believe its innovative features have the potential to significantly transform management of severe hypoglycemia,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Helping a diabetic patient through an acute crisis of severe hypoglycemia can be a highly traumatic experience. Our vision is for every patient at risk of severe hypoglycemia to have the HypoPal® rescue pen readily available.”

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Adam Steensberg, Executive Vice President and Chief Medical & Development Officer

Tel.: +45 50 60 36 01, e-mail: ast@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

Dasiglucagon (glucagon analog stable in liquid formulation) for use in other indications

Dasiglucagon is a Zealand-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of type 1 diabetes with a next-generation artificial pancreas, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).

About t

ype 1 diabetes and hypoglycemia

People with type 1 diabetes suffer from insulin deficiency and inappropriate glucagon secretion. Both hormones are essential to ensure stable and healthy blood glucose levels. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.

Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy. Severe hypoglycemia occurs most frequently in people with type 1 diabetes due to injecting insulin multiple times daily. It is the biggest concern for insulin-dependent patients and the most feared complication of diabetes treatment. The condition is characterized by confusion, seizures, and often loss of consciousness that can result in death if left untreated.

When a patient has a hypoglycemic event, a second person must assist in treatment. Currently marketed formulations of glucagon for the treatment of severe hypoglycemia require mixing first by the person assisting to treat and then immediate administration due to poor drug stability. Dasiglucagon is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. 



Relateret indhold
03 jun - 
Zealand Pharma/Bryan Garnier: Løfter kursmål til 180 kr..
24 maj - 
Zealand Pharma/SHB: Kursmålet løftes mens anbefalingen ..
22 maj - 
Onsdagens aktier: Overbevisende regnskab sendte Simcorp..
Relateret debat
25 jun - 
Beklager, det virker ikke for mig.
25 jun - 
Er det et muligt bull flag vi ser?
24 jun - 
"Zealand Pharma has yet not found a new CFO. When do yo..

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 jun
Zealand Pharma starter website for kort-tarms syndrom patienter (SBS = Short Bowel Syndrom). I mine ..
24 jun
ZP er begyndt at rekruttere i et first in human P1-studie med GLP1/GLP2 dual agonist mod SBS:    htt..
24 jun
"Zealand Pharma has yet not found a new CFO. When do you expect to be able toannounce this position ..
24 jun
@Eliot   Der var Q&A med den nye CEO på proinvestor i sidste måned - har du læst det? Der er nogle f..
24 jun
Det er lidt vildt. De må virkelig tror på dette. De har 64 forsøgspersoner de vil tage ind i forsøge..
24 jun
Hvornår kommer der en melding på CFO? Jeg havde det indtryk af en ny CFO lige var på trapperne ved Q..

Vestas indgår forlig med GE i patentsag: Betaler fortroligt beløb

25-06-2019 16:36:29
Vestas har indgået forlig med den amerikanske rival Generel Electric i forbindelse med flere patentsager. Det betyder, at sagerne nu droppes, oplyser de to selskaber i en meddelelse.Vestas betaler i forbindelse med forliget en fortrolig sum penge til GE. Derudover giver forliget en krydslicens til paterne, der omhandler teknologi, der bruges til at sikre stabiliteten i vindmøllerne under forstyrre..

Amerikanske medicinalvirksomheder slår sig sammen i millardhandel

Relaterede nyheder
25-06-2019 13:05:35
Den amerikanske medicinalvirksomhed Abbvie overtager sin kollega Allergan i en handel til en værdi af 63 mia. dollar.Det bekræfter de to selskaber, efter at Wall Street Journal tidligere tirsdag kunne citere kilder for, at opkøbet var på vej.Ifølge aftalen betaler Abbvie 188,24 dollar per aktie i Allergan, svarende til en præmie på 45 pct. sammenlignet med lukkekursen på Allergan mandag.Aktien i A..

Mærsk lancerer nyt onlineprodukt: Vil bryde med overbookinger

25-06-2019 10:36:22
(Korr: ændring i andet afsnit. Ordet "betales" er ændret til "aftales".)A.P. Møller-Mærsk lancerer et nyt onlineprodukt, der skal være med til at gøre transporten af containere mere simpel for kunderne, og som samtidig kan være med til at undgå overbookinger.Produktet går under navnet Maersk Spot, og det sikrer kunderne en garanti for, at fragten bliver lastet, skriver Mærsk i en pressemeddelelse ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
Britisk investeringsfirma reducerer shortposition i to danske aktier
Danske Bank/Nordea: Sænker kursmål med 10 kr.
Detektivfirma: Danske Bank fyrede os af frygt for hvidvasksag
Aktier/tendens: Inspirationen hælder mest til den negative side
Ørsted lægger to enheder sammen: Koncerndirektør forlader selskabet

Relaterede aktiekurser

Zealand Pharma A/S 139,90 1,5% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 139,90 1,5% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
26. juni 2019 00:12:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-26 00:12:12 - 2019-06-26 00:12:12 - 1 - Website: OKAY